SCHEMBL2931957

SCHEMBL2931957

CC(C)(C)OC(=O)N1CC2CC2C1CNc1ncc(Br)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.36
IDO1 P14902 1/20 0.36
TDO2 P48775 1/20 0.36
HDAC1 Q13547 3/20 0.35
HCRTR2 O43614 2/20 0.35
HSD11B1 P28845 1/20 0.34
GPR119 Q8TDV5 2/20 0.34
KMT2A Q03164 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
NR1H2 P55055 1/20 0.33
JAK3 P52333 1/20 0.33
F13A1 P00488 2/20 0.32
TGM2 P21980 2/20 0.32
TGM1 P22735 2/20 0.32
KCNK3 O14649 2/20 0.32
KCNK9 Q9NPC2 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931958 1.00 HCRTR1 (0.36) HCRTR1IDO1TDO2HDAC1HCRTR2
SCHEMBL1340254 1.00 HCRTR1 (0.36) HCRTR1IDO1TDO2HDAC1HCRTR2
SCHEMBL984844 0.78 PREP (0.44) HCRTR1IDO1TDO2HDAC1HCRTR2
SCHEMBL889008 0.78 FPR3 (0.42) HCRTR1IDO1TDO2HDAC1GPR119
SCHEMBL12810103 0.76 FPR3 (0.49) HCRTR1HCRTR2KMT2A
SCHEMBL2925316 0.75 HCRTR1 (0.43) HCRTR1HCRTR2GPR119KMT2A
SCHEMBL4074408 0.75 HCRTR1 (0.43) HCRTR1HCRTR2GPR119KMT2A
SCHEMBL2925315 0.75 HCRTR1 (0.43) HCRTR1HCRTR2GPR119KMT2A
SCHEMBL7204445 0.75 PRMT5 (0.46) HCRTR1IDO1TDO2HCRTR2KMT2A
SCHEMBL889104 0.75 PRMT5 (0.46) HCRTR1IDO1TDO2HCRTR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079690-B1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-09-15 EP disclosed
EP-2185512-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-05-19 EP disclosed
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES Actelion Phamaceuticals Ltd. (CH) 2010-01-21 US disclosed
WO-2009016560-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016401-A1 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 HCRTR1 1/4885IDO1 516/4885TDO2 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.